Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 120

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 120
---
 the holder will be given the same choice as to the consideration it receives upon any exercise of either the Pre -FundedWarrants following such Fundamental Transaction. Right as a Stockholder:Except as otherwise provided in the Pre -FundedWarrants or by virtue of such holder’s ownership of shares of our Common Stock, the holders of the Pre -FundedWarrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they exercise their Pre -FundedWarrants. (B) February 2025 Common Warrants The following summary of certain terms and provisions of the February 2025 Common Warrants that are is not complete and is subject to, and qualified in its entirety by, the provisions of the February 2025 Common Warrant, the form of which is filed as Exhibit 4.7 to the registration statement filed with the SEC on February 5, 2025. Prospective investors should carefully review the terms and provisions of the form of February 2025 Common Warrant for a complete description of the terms and conditions of the February 2025 Common Warrants. 67 We issued and sold 2,551,020 February 2025 Common Warrants to purchase an aggregate of 2,551,020shares of our Common Stock. Each February 2025 Common Warrant has an exercise price per share of $1.96 and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the February 2025 Common Warrants (the “Warrant Stockholder Approval”) which we are seeking to obtain at our 2025 Annual Meeting of Stockholders. The February 2025 Common Warrants will expire on the 5 -yearanniversary of the Warrant Stockholder Approval. The February 2025 Common Warrants will be exercisable in whole or in part by delivering to the Company a completed instruction form for exercise and complying with the requirements for exercise set forth in the February 2025 Common Warrant. Payment of the exercise price may be made in cash, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the February 2025 Common Warrants. No Fractional Shares:No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the February 2025 Common Warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, the